iStock, rudall30 BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S. BioNTech is closing a Singapore production plant less than four years after buying the site from Novartis to supply mRNA vaccines and therapies in the Asia-Pacific region. When BioNTech bought the facility in November 2022, the company expected the facility to be fully operational in l

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted stock units to eleven new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The 141,000 restricted

Sweden-based biopharma Immedica revealed that lurbinectedin (Zepzelca) combined with atezolizumab has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as first-line maintenance therapy for extensive-stage small cell lung cancer, moving the combination closer to becoming the first approved regimen to improve survival beyond checkpoint inhibitor monotherapy in this setting. The opinion is based on data from the Phase III IMforte

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place M

FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of April 1, 2026 equity inducement awards to three new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were m

FRIDAY, April 3, 2026 — In its first "real-world" trial, the nerve stimulation treatment called TENS appeared to reduce the pain and tiredness of fibromyalgia. "The study shows that TENS provides an added benefit on top of any relief from other treatments," said study first author Dana Dailey of the University of Iowa. "All the study participants were also using pain medications and receiving physical therapy, yet TENS still provided additional relief," noted Dailey, who is an assistant researc

Johns Hopkins University has received a UM1 cooperative agreement award of USD 2,856,513 from the National Center for Advancing Translational Sciences for fiscal year 2026. The funding is to support the development of the Drug Research Organoid-Integrated Development platform, known as DROIDp, a human iPSC-derived brain organoid system designed to model learning and memory processes in vitro for neurodevelopmental disorder research and chemical safety testing. The platform combines 3D brain orga

Thermo Fisher Scientific, a life sciences tools and services company headquartered in Waltham, Massachusetts, has launched the Gibco CTS Compleo fill and finish system , an automated platform designed to streamline formulation and filling in cell therapy manufacturing. The system is intended to address variability and contamination risks associated with manual fill-finish workflows, which have traditionally required careful handling of fragile cells in small volumes, according to the announcemen

NAARDEN, the Netherlands and MIAMI, April 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterda

PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which directly and indirectly holds 26.03% of Ipsen S.A.’s share capital and 33.05% of its voting rights — has obtained from the French Financial Markets Authority (Autorité des marchés financiers) an exemption from the obligation to public tender offer for all Ipsen S.A. shares. 1 This decision is part of the transfer of Mr. Henri Beaufour’s stake in Beech Tree to the Alasol Foundation. This transfer is